Evidence map›Paper›PMID 39478506›Full record

ArticleBMC cancer2024

B7-H3 is widely expressed in soft tissue sarcomas.

Meghan M Lynch, Rusul Al-Marayaty, Farres Obeidin, Borislav A Alexiev, Eleanor Y Chen, Pedro Viveiros, Brett A Schroeder, Kelly Hudkins, Timothy M Fan, Mary W Redman and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Adoptive T-Cell Therapy in Sarcomas.Current oncology reports · 2025
    Review
  9. Article
  10. Review
  11. Targeted treatment for craniopharyngioma.Journal of neuro-oncology · 2025
    Review
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Meghan M Lynch *Department of Internal Medicine, Northwestern University, Chicago, IL, USA.
Rusul Al-Marayaty *Department of Medicine, Division of Oncology, Northwestern University, 303 E. Superior St. #3-115, Chicago, IL, 60611, USA.
Farres ObeidinDepartment of Pathology, Northwestern University, Chicago, IL, USA.
Borislav A AlexievDepartment of Pathology, Northwestern University, Chicago, IL, USA.
Eleanor Y ChenDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.
Pedro ViveirosDepartment of Medicine, Division of Oncology, Northwestern University, 303 E. Superior St. #3-115, Chicago, IL, 60611, USA.
Brett A SchroederNational Cancer Institute, NIH, Bethesda, MD, USA.
Kelly HudkinsDepartment of Pathology, Northwestern University, Chicago, IL, USA.
Timothy M FanDepartment of Veterinary Clinical Medicine, University of Illinois at Urbana-Champaign, Champaign, IL, USA.
Mary W RedmanDepartment of Clinical Biostatistics, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Kelsey K BakerDepartment of Clinical Biostatistics, Fred Hutchinson Cancer Center, Seattle, WA, USA.
George JourDepartment of Pathology, New York University, New York, NY, USA.
Lee D CranmerDivision of Medical Oncology, University of Washington and Clinical Research Division of the Fred Hutchinson Cancer Center, Seattle, WA, USA.
Seth M PollackDepartment of Medicine, Division of Oncology, Northwestern University, 303 E. Superior St. #3-115, Chicago, IL, 60611, USA. seth.pollack@northwestern.edu.

Funding

Novel IL-12 Gene Delivery Vehicles for Transformation of Solid TumorsR01CA244872 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI POLLACK, SETH M · 2020 to 2024
$2.5M
NCI NIH HHS R01 CA244872NCI NIH HHS R01CA244872
6 · The paper itself

Abstract

purposeTargeted therapy development in soft tissue sarcoma (STS) has been burdened by the heterogeneity of this group of rare tumors. B7 homolog 3 protein (B7-H3) is a molecule in the same family as programmed death-ligand 1 (PD-L1). It has limited expression in noncancerous tissues and is overexpressed in many cancers, making it an attractive target for cancer therapy, and clinical trials targeting B7-H3 are actively underway. While available data demonstrate high expression levels of B7-H3 in individual sarcoma subtypes, its expression patterns across STS subtypes are not well described. The purpose of this study was to characterize the expression patterns of B7-H3 in STS. PATIENTS AND

methodsThis retrospective analysis evaluated STS tumor specimens from patients with a variety of different subtypes. Specimens were evaluated by immunohistochemistry (IHC) for expression and staining pattern of B7-H3 both in tumors and in associated vasculature.

resultsSpecimens from 153 sarcoma patients included 15 different STS subtypes. B7-H3 was broadly expressed in 97% of samples (95% CI 0.93-0.99) and 69.2% demonstrated high levels of B7-H3 expression (95% CI 0.61-0.76). No significant association between B7-H3 positivity or expression level and prior treatment(s), tumor size, tumor grade, or patient age. B7-H3 positivity in vessels was found in 94.7% (145/153) of samples. In tumors that had been previously assessed for PD-L1 and PD-1, there was no correlation between B7-H3 positivity or expression and the positivity or expression level of PD-L1 or PD-1.

conclusionThese data show high levels of B7-H3 positivity across soft tissue sarcoma subtypes, suggesting its feasibility as a therapeutic target for future sarcoma treatments. Future clinical trials are needed to evaluate whether targeting B7-H3 can provide clinical benefit to help patients with sarcoma.

Indexed as

B7 AntigensSarcomaAdolescentAdultAgedAged, 80 and overBiomarkers, TumorFemaleHumansImmunohistochemistryMaleMiddle AgedRetrospective StudiesYoung AdultB7 AntigensBiomarkers, TumorCD276 protein, humanB7-H3ImmunotherapySarcomaSoft tissue sarcomaTherapeutic target

Identifiers

PMID39478506
PMCPMC11523878

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.